Evidence map›Paper›PMID 37804407›Full record

ReviewMolecular biotechnology2024

Evaluation of Long Non-coding RNA (LncRNA) in the Pathogenesis of Chemotherapy Resistance in Cervical Cancer: Diagnostic and Prognostic Approach.

Noushin Modabber, Sarah Sadat Mahboub, Sahar Khoshravesh, Fatemeh Karimpour, Anita Karimi, Vahid Goodarzi

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Noushin Modabber *Shahid Akbar-Abadi Clinical Research Development Unit (SHACRDU), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Sarah Sadat Mahboub *Shahid Akbar-Abadi Clinical Research Development Unit (SHACRDU), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Sahar KhoshraveshShahid Beheshti University of Medical Science, Tehran, Iran.
Fatemeh KarimpourCancer Reserch Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Anita KarimiShahid Beheshti University of Medical Science, Tehran, Iran.
Vahid GoodarziDepartment of Anesthesiology, Rasoul-Akram Medical Center, Iran University of Medical Sciences (IUMS), Tehran, Iran. vahid396396@gmail.com.ORCID http://orcid.org/0000-0002-6632-453X
Iran University of Medical Sciences · IRShahid Beheshti University · IRBabol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC), caused by human papillomavirus (HPV), is a leading cause of female malignancies worldwide. Therefore, understanding the underlying mechanisms of CC development and identifying novel therapeutic targets are significantly important. Cisplatin resistance is a significant challenge in the management of CC. Recent studies highlighted the critical role of long non-coding RNAs (lncRNAs) in modulation of cisplatin resistance. This comprehensive review aims to collect the current understanding roles of lncRNAs and their involvement in cisplatin resistance in CC by highlighting key processes of cancer progression, including apoptosis, proliferation, angiogenesis and epithelial-to-mesenchymal transition (EMT). We discussed the role of lncRNA in CC resistance to cisplatin through molecular pathways and examined gene expression changes. We also discussed treatment strategies and factors that reduce CC resistance to cisplatin by targeting them.

Indexed as

CisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticRNA, Long NoncodingUterine Cervical NeoplasmsAntineoplastic AgentsApoptosisEpithelial-Mesenchymal TransitionFemaleHumansPrognosisAntineoplastic AgentsCisplatinRNA, Long NoncodingAngiogenesisApoptosisCervical cancerCisplatin resistanceEMTLncRNAProliferation

Identifiers

PMID37804407
OpenAlexW4387423178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.